Sol-Gel Technologies Ltd. (SLGL)

IL — Healthcare Sector
Peers: MOLN  ANEB  OBIO  RZLT  VRCA  URGN  SCPH  EVLO  EYEN 

Automate Your Wheel Strategy on SLGL

With Tiblio's Option Bot, you can configure your own wheel strategy including SLGL - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol SLGL
  • Rev/Share 4.3446
  • Book/Share 7.2411
  • PB 1.0178
  • Debt/Equity 0.0584
  • CurrentRatio 5.124
  • ROIC 0.1643

 

  • MktCap 20531051.0
  • FreeCF/Share 0.0
  • PFCF 0.0
  • PE -1.574
  • Debt/Assets 0.0436
  • DivYield 0
  • ROE -0.4398

 

  • Rating C
  • Score 2
  • Recommendation Sell
  • P/E Score 1
  • DCF Score 1
  • P/B Score 4
  • D/E Score 3

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
Downgrade SLGL Raymond James Strong Buy Outperform $6 $4 Aug. 19, 2024

News

Sol-Gel Reports First Quarter 2025 Results
SLGL
Published: May 23, 2025 by: GlobeNewsWire
Sentiment: Neutral

NESS ZIONA, Israel, May 23, 2025 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a clinical-stage dermatology company, today announced financial results for the first quarter ended March 31, 2025.

Read More
image for news Sol-Gel Reports First Quarter 2025 Results
Sol-Gel Announces Reverse Share Split
SLGL
Published: May 01, 2025 by: GlobeNewsWire
Sentiment: Neutral

NESS ZIONA, Israel, May 01, 2025 (GLOBE NEWSWIRE) -- Sol-Gel Technologies Ltd. (the “Company”) (NASDAQ: SLGL), a clinical-stage dermatology company, today announced a reverse share split (the “Reverse Split”) of the Company's issued and outstanding ordinary shares, par value NIS 0.1 per share (the “Ordinary Shares”), at the ratio of 10-for-1, such that each ten (10) Ordinary Shares shall be consolidated into one (1) Ordinary Share.

Read More
image for news Sol-Gel Announces Reverse Share Split
Global Sol-Gel Coatings Market Research 2025-2035: Competitive Landscape, Functional Properties and Applications, End-users, Technology Fundamentals, Overview and Growth Analysis
SLGL
Published: April 07, 2025 by: GlobeNewsWire
Sentiment: Neutral

This detailed market intelligence publication offers valuable insights into the innovative technologies, competitive landscape, and emerging opportunities that are reshaping the global surface engineering industry through 2035. This detailed market intelligence publication offers valuable insights into the innovative technologies, competitive landscape, and emerging opportunities that are reshaping the global surface engineering industry through 2035.

Read More
image for news Global Sol-Gel Coatings Market Research 2025-2035: Competitive Landscape, Functional Properties and Applications, End-users, Technology Fundamentals, Overview and Growth Analysis

About Sol-Gel Technologies Ltd. (SLGL)

  • IPO Date 2018-02-01
  • Website https://www.sol-gel.com
  • Industry Biotechnology
  • CEO Moshe Arkin
  • Employees 34

Sol-Gel Technologies Ltd., a clinical stage specialty pharmaceutical company, focuses on developing and commercializing topical dermatological drug products based on its proprietary microencapsulation delivery system in Israel. The company's lead product candidates include Twyneo, a novel, once-daily, non-antibiotic topical cream which has completed Phase III clinical trials for the treatment of acne vulgaris; Epsolay, a once-daily topical cream that has completed Phase III clinical trials for the treatment of papulopustular rosacea; SGT-210, which is in Phase I clinical trial for the treatment of palmoplantar keratoderma; and Erlotinib, Tapinarof, and roflumilast to treat psoriasis and other medical conditions. It is also involved in the development of generic topical dermatological drug products. The company has collaboration with Perrigo. Sol-Gel Technologies Ltd. was incorporated in 1997 and is headquartered in Ness Ziona, Israel.